Part of the Experience Rochester series presented by the University of Rochester Alumni Board

Neurology and neuromuscular medicine are leading the way in the rapidly expanding field of in vivo gene therapy. In December 2018, University of Rochester Medical Center (URMC) neurologists delivered gene therapy to an infant born with spinal muscular atrophy (SMA), a condition similar to Lou Gehrig’s disease, and a diagnosis that was previously either fatal or meant a lifetime of severe disability. Since then, the SMA gene therapy program has grown, and children with SMA now live near-normal lives. In 2022, children that came to URMC were among the first to receive an experimental gene therapy for Duchenne muscular dystrophy. These treatments are part of an accelerating trend of research and clinical trials involving gene therapies that marshal the renowned expertise in our Department of Neurology and could transform how we treat many other debilitating neurological disorders.

Join URMC neurologists Emma Ciafaloni, MD, Bo Hoon Lee ’13M (MD), ’18M (Res), and Samuel J. Mackenzie, MD, PhD for a talk on how far we’ve come in treating these devastating neurological diseases, and the optimistic future for many similar conditions.

Event Details

  • Molly Davis

1 person is interested in this event

User Activity

My first symptoms of ALS occurred in 2014, but were diagnosed in 2016. I had severe symptoms ranging from shortness of breath, balance problems, couldn't walk without a walker or a power chair, i had difficulty swallowing and fatigue. I was given medications which helped but only for a short burst of time, then I decided to try alternative measures and began on ALS Formula treatment from Tree of Life Health clinic. It has made a tremendous difference for me (Visit w w w. healthcareherbalcentre .com I had improved walking balance, increased appetite, muscle strength, improved eyesight and others. ]